Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Benzinga
AUGUST 4, 2022
AstraZeneca/Merck's Lynparza Scores European Approval In Early Breast Cancer. Syros Bone Marrow Cancer Candidate Poised To Get European Orphan Drug Tag. Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus.
Let's personalize your content